Understanding HoLEP - Advances in Prostate Treatment - Dr Jeevagan Murugesan

Published Date: 01 Mar 2023

Benign prostatic hyperplasia (BPH) is a condition in which the prostate gland enlarges, causing problems or obstruction in urination...

Read Full News

Latest News

Experimental Novartis Radiopharma Drug Shows Promise in Early Study

Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in ⁠patients...

Vasectomy Reversal More Cost-Effective Than IVF

Most couples younger than 40 years can achieve pregnancy within typical $30,000-$40,000 employer fertility benefits with reversal, new research indicates.

US Judge Rejects Bayer Bid to Block Johnson & Johnson Prostate Cancer Drug Claims

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

This Test Could Predict Incontinence Risk After HoLEP

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

Smartphone App Helps Delay Ejaculation

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

US FDA Approves Lantheus' New Prostate Cancer Imaging Formulation

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Todays Updates

FDA Grants Emergency Approval for Over-the-counter Drug to Treat Screwworm in Pets

The U.S. Food and Drug Administration on Thursday authorized the emergency use of a generic over-the-counter tablet ⁠to treat infestations caused by the New World screwworm...

Highlights in Prostate Cancer From AUA 2026

Extent of lymph node dissection, defining high-risk criteria, oral androgen deprivation therapy (ADT), and darolutamide plus ADT are among the highlights for prostate cancer management from AUA 2026.

New Imaging Agent Could Speed Detection of AD-Related Tau

A novel PET imaging agent identified AD-related tau earlier and in more patients than the currently used tracer, possibly speeding AD detection, a new study shows.

CMS Rule Misses Mark on CPAP Adherence

A Kaiser Permanente study shows some people who initially struggle with CPAP adherence still use the device at 1 year, suggesting CMS’ 90-day cutoff is too strict.

Good Outcomes with Ublituximab in First Real-World Study

Even though the real-world patients in a phase 4 study were older and heavier, ublituximab provided safety and tolerability at least comparable to that in 2 pivotal trials.

Organon Wins US Approval to Widen Use Of Arthritis Biosimilar Drug

Organon said on Wednesday the U.S. Food and Drug Administration has approved the expanded ⁠use of its arthritis drug, a biosimilar to Roche's Actemra, to treat a...

Ebola Testing Stalled in Three Congo Labs Due to Shortages, Says WHO

Three laboratories in Democratic Republic of Congo have run out of supplies to test for Ebola, the World ⁠Health Organization said, as the outbreak of the dangerous...

Todays Updates

FDA Grants Emergency Approval for Over-the-counter Drug to Treat Screwworm in Pets

The U.S. Food and Drug Administration on Thursday authorized the emergency use of a generic over-the-counter tablet ⁠to treat infestations caused by the New World screwworm...

Highlights in Prostate Cancer From AUA 2026

Extent of lymph node dissection, defining high-risk criteria, oral androgen deprivation therapy (ADT), and darolutamide plus ADT are among the highlights for prostate cancer management from AUA 2026.

New Imaging Agent Could Speed Detection of AD-Related Tau

A novel PET imaging agent identified AD-related tau earlier and in more patients than the currently used tracer, possibly speeding AD detection, a new study shows.

CMS Rule Misses Mark on CPAP Adherence

A Kaiser Permanente study shows some people who initially struggle with CPAP adherence still use the device at 1 year, suggesting CMS’ 90-day cutoff is too strict.

Good Outcomes with Ublituximab in First Real-World Study

Even though the real-world patients in a phase 4 study were older and heavier, ublituximab provided safety and tolerability at least comparable to that in 2 pivotal trials.

Organon Wins US Approval to Widen Use Of Arthritis Biosimilar Drug

Organon said on Wednesday the U.S. Food and Drug Administration has approved the expanded ⁠use of its arthritis drug, a biosimilar to Roche's Actemra, to treat a...

Ebola Testing Stalled in Three Congo Labs Due to Shortages, Says WHO

Three laboratories in Democratic Republic of Congo have run out of supplies to test for Ebola, the World ⁠Health Organization said, as the outbreak of the dangerous...

Latest News

Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in ⁠patients...

Most couples younger than 40 years can achieve pregnancy within typical $30,000-$40,000 employer fertility benefits with reversal, new research indicates.

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

News All Time

FDA Approves New Treatment for Women's Simple UTIs.

Now available in the U.S. is an antibiotic that is widely used in other nations. s.

During the Accountable Care Meeting, CMS Officials were pressed on the topic of scanner fraud.

"We would appreciate it if you could give the matter more immediate attention," one ACO member said.

Nivolumab Plus Chemotherapy in First Line Approved for Bladder Cancer.

Combination decreased death risk by 22%.

King Charles III's Operation; COVID-19 Timeline Under Question; FDA Approvals Reach Record High.

The staff of MedPage Today has compiled health news and commentary from around the web.

Noninvasive Treatment Effective in Bladder Cancer That Is Not Muscle-Invasive.

An investigational intrusive solution produced a 79% complete response rate.

For Prostate Cancer at Intermediate Risk, SBRT Is Not Less Effective Than Conventional RT.

Similar results are obtained from treatment lasting one to two weeks as compared to therapy lasting up to seven and a half weeks.

The new first-line standard for advanced bladder cancer was produced by a landmark trial.

When compared to chemotherapy, enfortumab vedotin-pembrolizumab doubles OS and PFS.

Should Patients With Advanced Prostate Cancer Get Off the Active Surveillance Train?

Clearly defined rules are needed.

Even in those with HIV, a single dose of antibiotics was able to cure early syphilis.

In a randomized trial, one dosage showed no worse results than a triple-dose regimen.

Removing Cancer Survivors From Oncologic Treatment.

A new approach to care is required.

Cabazitaxel Lower-Dose Schedule Is Viable for Elderly Patients With mCRPC.

Neutropenia of grade three or above, with a twelve-fold reduction in neutropenic consequences.

AR-Pathway Inhibitor Switch for mCRPC is Superseded by Radionuclide Therapy.

With 177Lu-PSMA-617, the time to radiographic progression was doubled.

An RCT Supports HIF-2a Inhibition in Advanced RCC.

Belzutifan outperforms everolimus in the event of immunotherapy-TKI failure.

In severe cases of renal cell carcinoma, tyrosine kinase inhibitor activity is present.

Reactions to the "special medication" zanzalintinib in patients exposed and not exposed to cabozantinib.

CAR T-Cell Therapy for Renal Cell Carcinoma: "We're Not There Yet".

Possibility of standard of care following current therapies, but significant barriers still need to be overcome.

Finding New Routes to Improve Renal Cell Carcinoma Outcomes.

It is necessary to intervene at several stages of the cancer immunity cycle in order to build on recent successes.

Recommended News For You

'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning

How 7,000 steps a day could help reduce your risk of cancer

FDA Expands Approval of Osimertinib in Lung Cancer

Having dense breasts is linked to cancer, but advice about breast density can depend on where you live

Fighting for others: How guilt and obligation drive desire for more intensive treatments in end-of-life cancer care

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions

The Kansas Cancer Center awarded two Indian American doctors professorships.

Recommended Articles For You

Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options  

Demystifying Hypereosinophilic Syndrome: Symptoms, Diagnosis, and Treatment Options  

Comprehensive Developments in Hematology in Daily Practice 

Chloride Test in HCC: Diagnostic Utility, Prognostic Role, and Emerging Insights 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Retired Olympic athletes at greater risk of skin cancer and osteoarthritis, research reveals

2.

Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma

3.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

4.

Glofitamab Regimen Improves Survival in DLBCL

5.

iPSC-based vaccines: A new hope for preventing and treating colorectal cancer

1.

Unlocking the Potential of Talquetamab: A Revolutionary Approach to Cancer Treatment

2.

Demystifying Hematoma Rectus Sheath: Knowing the Symptoms and Causes

3.

Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia

4.

Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer

5.

How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.

2.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

4.

Efficient Management of First line ALK-rearranged NSCLC - Part VII

5.

CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot